From the publishers of JADPRO

Cardio-Oncology Updates

Select Category

  • Immune Checkpoint Inhibitors
  • Kinase Inhibitors
  • HER2-Targeted Therapies
  • Novel Immunotherapies (CAR-T, BiTE)
  • Home
  • Class Categories
    • Immune Checkpoint Inhibitors
    • Kinase Inhibitors
    • HER2-Targeted Therapies
    • Novel Immunotherapies (CAR-T, BiTE)
  • Cardio-Oncology Basics
  • Meet the Faculty
  • Message from the Program Chair
  • Case Studies
    • Immune Checkpoint Inhibitors
    • Kinase Inhibitors
    • HER2-Targeted Therapies
    • Novel Immunotherapies (CAR-T, BiTE)
  • Fast Facts
    • Immune Checkpoint Inhibitors
    • Kinase Inhibitors
    • HER2-Targeted Therapies
    • Novel Immunotherapies (CAR-T, BiTE)
  • Videos
  • Resources
  • News & Literature Highlights
  • Visit JADPRO Online
  • Contact

.

Home Cardio-Oncology Basics

Cardio-Oncology Basics


Chapter 7

Cardio-Oncology Basics: Conclusions

Download Slides



  • Chapter 1


    7:35

    What is Cardio-Oncology?


  • Chapter 2


    11:46

    Link Between Cancer, Treatment, and Heart Disease


  • Chapter 3


    8:49

    Cardio-Oncology Standards of Care


  • Chapter 4


    4:24

    CV Evaluation of Patients Before and During Cancer Therapy


  • Chapter 5


    3:32

    Cancer Treatment–Related Cardiotoxicity


  • Chapter 6


    12:33

    Breast Cancer Drugs and Cardiotoxicity


  • Chapter 7


    2:07

    Cardio-Oncology Basics: Conclusions

Class Categories
  • Immune Checkpoint Inhibitors

  • Kinase Inhibitors

  • HER2-Targeted Therapies

  • Novel Immunotherapies (CAR-T, BiTE)

Meet the Faculty

Resources
  • General Cardio-Oncology The Cancer Patient and Cardiology

  • General Cardio-Oncology The Role of Cardiovascular Imaging in Cancer Patients Receiving Cardiotoxic Therapies: A Position Statement on Behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio‐Oncology Council of the European Society of Cardiology (ESC)

  • General Cardio-Oncology Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools From the Cardio-Oncology Study Group of the Heart Failure Association of the European Society

  • General Cardio-Oncology NCCN Clinical Practice Guidelines in Oncology: Survivorship Version 2.2020

  • General Cardio-Oncology Cardiovascular and Cancer Risk: The Role of Cardio-Oncology

View More
Videos
  • Novel Immunotherapies Managing Cardiotoxicity Associated With BiTE Therapy: A Case Study

  • HER2-Targeted Therapies Monitoring and Management Strategies for HER2-Targeted Therapy–Associated Cardiotoxicity

  • Immune Checkpoint Inhibitors Managing Cardiotoxicity Associated With Immune Checkpoint Inhibitor Therapy

  • Kinase Inhibitors Managing Ibrutinib-Associated Cardiotoxicity in CLL: A Case Study

  • HER2-Targeted Therapies HER2-Targeted Therapies: Cardiotoxicity Incidence

View More